短期应用仙灵骨葆联合柳氮磺胺吡啶维持治疗强直性脊柱炎的疗效

Effect of xianlinggubao combined with sulfasalazine in a short period on maintenance treatment of patients with ankylosing spondyloarthritis

目的探讨短期应用仙灵骨葆联合柳氮磺胺吡啶(SSZ)治疗强直性脊柱炎(AS)的临床疗效。方法 60例AS患者分成实验组和对照组各30例。实验组口服仙灵骨葆胶囊及SSZ连续12个周,对照组口服SSZ治疗12个周。于第1、3、6、12周评价患者的强直性脊柱炎病情活动指数(BASDAI)、巴氏强直性脊柱炎功能指数(BASFI)、BASDAI和BASFI改善百分比、血沉(ESR)、C反应蛋白(CRP)、AS20%、AS50%。结果第1个周后,2组BASDAI评分相比有显著差异。治疗第3个周后,2组BASFI评分相比有显著差异。治疗第6、12个周后,2组BASDAI评分及BASFI评分相比均有显著差异。实验组ESR、CRP在治疗1周后即出现持续下降,而对照组3个周后呈持续下降。2组治疗过程中均无严重不良反应。结论应用仙灵骨葆胶囊联合SSZ治疗AS患者的效果优于单用SSZ。

Objective To explore the clinical effect of xianlinggubao combined with sulfasalazine（ SSZ） on treatment of patients with ankylosing spondyloarthritis. Methods Sixty patients with AS were divided into experimental group and control group,30 cases in each group. The experimental group was treated with xianlinggubao combined with SSZ for 12 weeks,while the control group was treated with SSZ. After treatment of 1,3,6,12 weeks,BASDAI,BASFI,improved percentage,ESR,CRP,AS20% and AS50% were evaluated and compared between two groups. Results One week after treatment,there was significant difference of BASDAI between two groups. Three weeks after treatment,there was significant difference of BASFI between two groups. Six and twelve weeks after treatment,there were significant differences of BASDAI and BASFI between two groups. ESR and CRP in the experimental group declined continuously after one week of treatment,while there was a declining trend 3 weeks after treatment in the control group. There were no severe adverse reactions in both groups. Conclusion Application of xianlinggubao combined with SSZ in the treatment of AS is better than SSZ.